vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $349.1M, roughly 1.0× PROCORE TECHNOLOGIES, INC.). LivaNova PLC runs the higher net margin — 8.6% vs -10.8%, a 19.3% gap on every dollar of revenue. On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs 12.1%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $50.2M). Over the past eight quarters, PROCORE TECHNOLOGIES, INC.'s revenue compounded faster (13.8% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
LIVN vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $349.1M |
| Net Profit | $30.9M | $-37.6M |
| Gross Margin | 65.2% | 80.1% |
| Operating Margin | 11.8% | -12.3% |
| Net Margin | 8.6% | -10.8% |
| Revenue YoY | 12.1% | 15.6% |
| Net Profit YoY | -44.7% | 39.6% |
| EPS (diluted) | $0.57 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $349.1M | ||
| Q3 25 | $357.8M | $338.9M | ||
| Q2 25 | $352.5M | $323.9M | ||
| Q1 25 | $316.9M | $310.6M | ||
| Q4 24 | $321.8M | $302.0M | ||
| Q3 24 | $318.1M | $295.9M | ||
| Q2 24 | $318.6M | $284.3M | ||
| Q1 24 | $294.9M | $269.4M |
| Q4 25 | $30.9M | $-37.6M | ||
| Q3 25 | $26.8M | $-9.1M | ||
| Q2 25 | $27.2M | $-21.1M | ||
| Q1 25 | $-327.3M | $-33.0M | ||
| Q4 24 | $55.9M | $-62.3M | ||
| Q3 24 | $33.0M | $-26.4M | ||
| Q2 24 | $16.3M | $-6.3M | ||
| Q1 24 | $-41.9M | $-11.0M |
| Q4 25 | 65.2% | 80.1% | ||
| Q3 25 | 68.4% | 79.7% | ||
| Q2 25 | 67.8% | 79.1% | ||
| Q1 25 | 69.7% | 79.1% | ||
| Q4 24 | 68.2% | 81.2% | ||
| Q3 24 | 70.8% | 81.4% | ||
| Q2 24 | 68.7% | 83.1% | ||
| Q1 24 | 70.3% | 83.0% |
| Q4 25 | 11.8% | -12.3% | ||
| Q3 25 | 15.1% | -4.4% | ||
| Q2 25 | 15.4% | -9.3% | ||
| Q1 25 | 15.3% | -11.7% | ||
| Q4 24 | 11.5% | -21.9% | ||
| Q3 24 | 11.2% | -12.3% | ||
| Q2 24 | 12.6% | -5.2% | ||
| Q1 24 | 5.5% | -7.0% |
| Q4 25 | 8.6% | -10.8% | ||
| Q3 25 | 7.5% | -2.7% | ||
| Q2 25 | 7.7% | -6.5% | ||
| Q1 25 | -103.3% | -10.6% | ||
| Q4 24 | 17.4% | -20.6% | ||
| Q3 24 | 10.4% | -8.9% | ||
| Q2 24 | 5.1% | -2.2% | ||
| Q1 24 | -14.2% | -4.1% |
| Q4 25 | $0.57 | $-0.25 | ||
| Q3 25 | $0.49 | $-0.06 | ||
| Q2 25 | $0.50 | $-0.14 | ||
| Q1 25 | $-6.01 | $-0.22 | ||
| Q4 24 | $1.04 | $-0.42 | ||
| Q3 24 | $0.60 | $-0.18 | ||
| Q2 24 | $0.30 | $-0.04 | ||
| Q1 24 | $-0.78 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $768.5M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $1.3B |
| Total Assets | $2.6B | $2.2B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $768.5M | ||
| Q3 25 | $646.1M | $684.0M | ||
| Q2 25 | $593.6M | $620.9M | ||
| Q1 25 | $738.4M | $566.7M | ||
| Q4 24 | $428.9M | $775.4M | ||
| Q3 24 | $346.4M | $756.9M | ||
| Q2 24 | $329.2M | $735.4M | ||
| Q1 24 | $309.2M | $744.6M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $2.6B | $2.2B | ||
| Q3 25 | $2.6B | $2.1B | ||
| Q2 25 | $2.5B | $2.0B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | $2.5B | $1.9B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $114.9M |
| Free Cash FlowOCF − Capex | $50.2M | $109.2M |
| FCF MarginFCF / Revenue | 13.9% | 31.3% |
| Capex IntensityCapex / Revenue | 8.9% | 1.6% |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $114.9M | ||
| Q3 25 | $85.1M | $88.5M | ||
| Q2 25 | $62.9M | $30.8M | ||
| Q1 25 | $24.0M | $66.0M | ||
| Q4 24 | $78.7M | $29.1M | ||
| Q3 24 | $51.0M | $39.3M | ||
| Q2 24 | $43.4M | $58.7M | ||
| Q1 24 | $10.0M | $69.1M |
| Q4 25 | $50.2M | $109.2M | ||
| Q3 25 | $62.2M | $83.1M | ||
| Q2 25 | $47.8M | $27.9M | ||
| Q1 25 | $13.2M | $62.0M | ||
| Q4 24 | $68.3M | $17.4M | ||
| Q3 24 | $32.8M | $35.7M | ||
| Q2 24 | $31.2M | $56.8M | ||
| Q1 24 | $3.6M | $67.1M |
| Q4 25 | 13.9% | 31.3% | ||
| Q3 25 | 17.4% | 24.5% | ||
| Q2 25 | 13.6% | 8.6% | ||
| Q1 25 | 4.2% | 20.0% | ||
| Q4 24 | 21.2% | 5.8% | ||
| Q3 24 | 10.3% | 12.1% | ||
| Q2 24 | 9.8% | 20.0% | ||
| Q1 24 | 1.2% | 24.9% |
| Q4 25 | 8.9% | 1.6% | ||
| Q3 25 | 6.4% | 1.6% | ||
| Q2 25 | 4.3% | 0.9% | ||
| Q1 25 | 3.4% | 1.3% | ||
| Q4 24 | 3.2% | 3.9% | ||
| Q3 24 | 5.7% | 1.2% | ||
| Q2 24 | 3.8% | 0.7% | ||
| Q1 24 | 2.2% | 0.8% |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
